Akums Drugs & Pharmaceuticals, India’s largest Contract Development and Manufacturing Organization (CDMO), has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its active pharmaceutical ingredient (API), Cefpodoxime Proxetil.

The CEP certification confirms that Akums’ manufacturing process and quality standards for Cefpodoxime Proxetil comply with the requirements of the European Pharmacopoeia. 

The approval is expected to support the company’s presence in regulated international markets and further strengthen its position as a reliable pharmaceutical manufacturing partner.

The development comes at a time when the global pharmaceutical industry is witnessing increasing demand for high-quality, compliant, and traceable APIs. 

The global API market is projected to continue its strong growth trajectory, driven by rising healthcare demand, increasing prevalence of infectious diseases, growing generic drug consumption, and stricter regulatory expectations across developed markets. 

Cefpodoxime Proxetil, a widely used cephalosporin antibiotic, continues to remain relevant in the treatment of multiple bacterial infections.

Arushi Jain, Director, Akums Drugs & Pharmaceuticals said, “The CEP approval for Cefpodoxime Proxetil reflects our continued focus on maintaining global quality and regulatory standards. This further supports our ability to cater to regulated markets and aligns with our vision of making high-quality and affordable pharmaceutical products accessible across geographies."